Scott Hepford is not a physician, but he is the driving force behind one of the most substantive developments in metabolic healthcare. Under his leadership, Well Cell Global developed and patented Physiologic Insulin Resensitization® (PIR®), a treatment protocol that rethinks how insulin is used in clinical settings.

Since 1922, insulin has been used as a drug to suppress high blood sugar after it occurs. PIR takes a fundamentally different approach: it administers insulin intravenously as a hormone communicator, precisely representative of the body's natural oscillating pattern of insulin secretion.

The treatment uses an FDA-approved portable pump paired with Well Cell's patented protocol to deliver insulin in a way that up-regulates insulin receptor activity, allowing glucose to more readily enter each cell and be used as fuel for conversion to energy. The result: damaged tissues and organs may begin to recover.